HEALTHY FOR LIFE

within this generation

Ann Belien, CEO | RejuvenateBiomed


80+
Rejuvenate
Biomed.com

Aging is not a problem

Age-related diseases are


Chronic disease
⬇ Physical function
⬇ Cognitive function
⬇ Resistance to infection


Rejuvenate
Biomed
RJx-01
Are you busy later? I need corrections made on the design project. Can we try some other colors?

Drug Repurposing Upside

Triple Drug Repurposing : combination & new formulation & new indication

Drug Repurposing Advantages

Availability of:

- ✓ Safety data
- ✓ Preclinical data
- ✓ Clinical trial/RWE data

- ✓ **Shorter development timelines**
- ✓ **Lower overall development risk**
- ✓ **Lower development costs**

Rejuvenate Biomed Advantage:

- ✓ **IP protection similar to NME**

Our way of working

Evaluate drugs for safety in target population

Investigate dysregulated genes/proteins/pathways

Identify drugs that restore molecular profiles

Combine:
- Synergistic (MOA)
- Safe (ADME-TOX)
- Patentable (IP)

Confirm efficacy
- C. elegans
- Mouse models

Proof of concept
- Human



What is aging

Hallmarks of aging

- genomic instability
- telomere attrition
- epigenetic alterations
- loss of proteostasis
- deregulated nutrient sensing
- mitochondrial dysfunction
- cellular senescence
- stem cell exhaustion
- altered intercell. communications

Age-related disease

- Diabetes
- Fatty liver disease
- Metabolic syndrome
- Sarcopenia
- Osteoporosis
- Cardiovascular disease
- Cognitive disorders

Adapted from López-Otin et al., Cell, 2013

What about the Regulatory challenge?

We solved this by using a short term strategic solution being sarcopenia.

WHY sarcopenia?

What is sarcopenia

Hallmarks of aging

genomic instability

telomere attrition

epigenetic alterations

loss of proteostasis

deregulated nutrient sensing

mitochondrial dysfunction

cellular senescence

stem cell exhaustion

altered intercell. communications

Age-related disease

Diabetes

Fatty liver disease

Metabolic syndrome

Sarcopenia

Osteoporosis

Cardiovascular disease

Cognitive disorders

Adapted from López-Otin et al., Cell, 2013


SARCOPENIA
Progressive loss of skeletal muscle mass/quality and strength.
Risk of physical disability, poor quality of life and death.
Affects 6-22% of 65+ year-olds, and 50% of 80+ year-olds.
Muscle disuse induced sarcopenia is an additional medical need: every person will be impacted in their live.
Recognized disease: ICD-10-CM (M62.84)
International diagnostic criteria
Approved endpoints
Rejuvenate
Biomed.com

What are the Mechanisms involved in sarcopenia

Neuromuscular junction



Decreased neurotransmission

Compromised mitochondria

Skeletal muscle

Enhanced muscular inflammation

Reduced autophagy

Mitochondrial dysfunction

Attenuated angiogenesis

Reduced nutrient signaling

Circulation

Inflammaging

RJx-01 targets overlapping & distinct processes of sarcopenia

Neuromuscular junction



- Decreased neurotransmission — A
- Compromised mitochondria — B

Skeletal muscle

- Enhanced muscular inflammation — A B
- Reduced autophagy — B
- Mitochondrial dysfunction — B
- Attenuated angiogenesis — A
- Reduced nutrient signaling — A B

Circulation

- Inflammaging — A B

Rejuvenate Biomed.com

Anticipated global sarcopenia patient population in M



Population ≥ 65 [1]

22% [2]

6% [2]

[1] *www.populationpyramid.net*
[2] *Dent et al., J Nutr Health Aging, 2018*

Balanced strategy



Sarcopenia landscape

HEALTHY FOR LIFE RejuvenateBiomed	**Small molecule**	**Phase Ib**	**Repurposing**	**RJx-01**
biophytis	Small molecule	Phase II	NME	BIO-101
Faraday PHARMACEUTICALS	Small molecule	Phase II	NME	FDY-5301
ARMGO Pharma, Inc. SERVIER	Small molecule	Phase I	NME	ARM-210
OPKO	Small molecule	Phase I	NME	OPK-88004
NOVARTIS REGENERON SANOFI	Large molecule	Discontinued	NME	Novartis: Strategic decision Regeneron: insufficient efficacy

18 NMEs in Preclinical Phase

RJx-01
Effective
in established aging models

C. elegans

Mouse
(OPA1)

RJx-01 Effective in established aging models

1. increases lifespan
2. enhances activity
3. protects muscle integrity

Mouse
(OPA1)

increases physical performance in old mice



Rejuvenate Biomed.com

RJx-01 Effective in established aging models

1. increases lifespan
2. enhances activity
3. protects muscle integrity

1. increases physical performance
2. improves muscle mass (OPA1)
3. improves muscle quality (OPA1)
4. reduces systemic inflammation (OPA1)

1. increases physical performance

Treadmill



Grip strength



2. improves muscle mass

Muscle mass



Cross-sectional area



3. improves muscle quality

Muscle absolute strength



Muscle specific strength



Rejuvenate
Biomed.com

4. reduces inflammation

Local, skeletal muscle



Systemic



Clinical plan in place

EMA-FAMHP-CAB

Study 1

Phase Ib randomized, double-blind, placebo-controlled, exploratory study in elderly, muscle impaired subjects.

RJx-01-101
Mechanistic POC & PK & target engagement & dose selection

Study 2a

Phase IIb randomized, double-blind, placebo-controlled study in sarcopenic patients.

Study 2b

Phase IIb randomized, double-blind, placebo-controlled study in “muscle disorder” patients.

Study 2c

Phase IIb randomized, double-blind, placebo-controlled study in “non-muscle related disorder” patients.

RJx-01-201
Clinical POC in optimal dose & individual compounds comparison

Next-generation Drug Combinations for Aging Diseases

Broad and renewable pipeline of anti-aging therapies…



… with accelerated development

Rejuvenate Biomed.com

Funding & Use

Series A €9 M

Platform

Validate elements:
in silico &
C. elegans via
collaboration

RJx-01

Clinical proof of concept **Mechanistic** human trial supporting multiple indications

Preclinical proof of concept **second and third indication**

Funding & Use

Series B 18 M

Platform

Validate
and internalize

RJx-01

Clinical proof of concept **sarcopenia**

Clinical proof of concept **second and third indication**

RJx-02

Preclinical proof of concept in animal model

NEW Road map and exit opportunities

RJx-02 - Clinical POC 1/2/3 - Ready for Phase III
RJx-03 - Mechanistic POC - Ready for Phase II
....



Rejuvenate
Biomed.com

Meet the management team

Ann Beliën, PhD, PMP
CEO

Ludo Haazen, MD
CMO

Evi Mercken, PhD
CSO

Lars Bastiaanse, PhD
COO

Lizzy-Anne Neven
CFO & HR

Janssen · Ablynx · Galapagos · NIH National Institute on Aging · TiGENIX Living Medicines · Roche · 3D PHARMEXCHANGE · Movetis · Shire · argenx · Kinesis · CARDIOLYSIS · ucb · astellas

Rejuvenate
Biomed.com

And our extended team

REJUVENATE BIOMED team	**MODIS** formerly CMAST strategic partner	**PhaRA** regulatory strategic partner	**BIOQUBE** business support	**JLABS** business support
JANSSEN Pharmaceutical companies of Johnson and Johnson drug dev. support	**CECAD** Cluster of Excellence for Aging Research, DE scientific collaborator	**NIA** National Institute on Aging, US scientific collaborator	**UNI. PADOVA** Venetian institute of aging, IT scientific collaborator	**KU LEUVEN & UGENT** C. elegans aging scientific collaborator
BDO Legal & Financial audit	**LC PATENTS** IP support	**EUROFINS** drug dev. support	**LAGA** legal support	**ERNST YOUNG** business support

Rejuvenate Biomed.com

Many thanks to our colaborators and advisors

Bart Braeckman, Prof, PhD
Ghent University, BE
Aging biology and molecular evolution



Rafael de Cabo, Prof, PhD
NIA, NIH, US
Study of Longitudinal Aging in Mice: SLAM



Marco Sandri, Prof, MD, PhD
University of Padova, IT
Sarcopenia



Björn Schumacher, Prof, PhD
University of Cologne, DE
CECAD Cluster of Excellence for Aging Research

Eric Verdin, Prof, MD, PhD
President and CEO
Buck Institute for Research on Aging, US



Johan Auwerx, Prof, MD, PhD
EPFL, Lausanne, CH
Mitochondrial function



Jean-Yves Reginster, Prof, MD, PhD
WHO Director
University of Liège, BE
Chairman Clinical Advisory Board

Jos Tournoy, Prof, MD, PhD
UZ Leuven, BE
Geriatric revalidation and frailty
Clinical Advisory Board member

Alfonso Cruz-Jentoft, Prof, MD, PhD
Madrid University, ES
Geriatric Medicine & Gerontology
Clinical Advisory Board member

Rejuvenate
Biomed.com

De-risked and fast development

Solid science

Big opportunity



Rejuvenate
Biomed.com

LET'S CONNECT!

invest@rejuvenatebiomed.com

Executive summary

Science-based healthy aging company

- Founded in 2017 as a spin-out of the Janssen Pharmaceutical Companies of Johnson & Johnson
- Develops therapies for age-related diseases to improve quality of life by repurposing prescription medicines (combination, new formulation, new indication) and providing strong IP protection

Next-generation drug repurposing platform

- Systems Biology: In silico identification of synergistic drug combinations based on clinical evidence, pathways & safety with the target population
- Broad and renewable pipeline

Highly potent repurposed drugs for aging & chronic diseases

Rapid pipeline generation of synergistic drug combinations

HEALTHY FOR LIFE
RejuvenateBiomed

Protected by strong IP

Accelerated development times and giant markets

Phase Ib/IIb ready, anti-aging compound RJx-01

- Combination drug with synergistic action on pathways of aging and sarcopenia
- Strong preclinical efficacy in sarcopenia models with well-known clinical safety
- Upside potential in COVID-19 immobilized and ICU acquired weakness patients: opportunity to accelerate and broaden strategy
- Additional targetable diseases based on preclinical data

Large & global market opportunities

- Large global increase in the 65+ elderly population: demand for new therapies for age-related diseases
- Global sarcopenia market: 50M patients in 2020, 100M in 2050, peak sales of € 1B with just a 2% market penetration in a limited region of 1.6M patients
- Broad targetable markets: muscle & non-muscle related diseases, orphan diseases & genetic disorders

€ 9M Series A: RJx-01 Mechanistic POC in human, PreClin POC 2nd indication RJx-01: inflection point
€ 18M Series B: RJx-01 phase II clinical POC in sarcopenia (&option 2 other indications) & RJx-02 preclinical POC: exit point